​Buy Fluvoxamine ( Floxyfral ) Cas 54739-18-3

​Buy Fluvoxamine ( Floxyfral ) Cas 54739-18-3

Fluvoxamine ( Floxyfral ) is an antidepressant medication used to treat major depressive episodes (i.e., characterized depressive episodes) in adults over 18 years of age and obsessive-compulsive disorder (OCD) in children over 8 years of age and adolescents. It is a selective serotonin reuptake inhibitor (SSRI ).

Its side effects include constipation , headaches , anxiety, irritability, sexual problems, dry mouth, sleep disturbances , and an increased risk of suicidality at the start of treatment due to the lifting of psychomotor inhibition. However, these side effects appear to be significantly less severe than with other SSRIs (see below).

Drugs , including alcohol, coffee and tobacco, should not be consumed while taking this medication and its prescription is not recommended for pregnant women and young people under eighteen years of age.

It can also cause manic episodes leading to aggressive and violent behavior. The dosage must be prescribed by a doctor.

In cases where there are sexual dysfunctions ( hypoactive sexual desire , anorgasmia , arousal disorder, etc.) prior to the onset of a depressive state, the use of fluvoxamine must be strictly avoided ^[ 2 ] .

Its effect multiplies that of caffeine in the human body by approximately 5, and it could cause serious adverse effects, including cardiac arrest, because it is a potent inhibitor of cytochrome P450-1A2 , which oxidizes caffeine, rendering it inactive. Fluvoxamine also inhibits the following CYP450 subunits: 2C9, 2D6, 2B6, 2C19, and 3A4. Therefore, drug interactions are numerous. Use with caution when taking medications such as diazepam, clonazepam, NSAIDs, and certain antidiabetic drugs. Combinations with olanzapine, imipramine, haloperidol, clomipramine, and tamoxifen are strongly contraindicated (increasing their plasma concentrations by a factor of 2 to 4).

Fluvoxamine may have a (very modest) sedative effect due to the presence of the trifluoro halogenated compound on the aromatic ring.

Fluvoxamine has been tested in combination with amitriptyline in an outpatient setting as a treatment for major depression in a small and insignificant study ^[ 3 ] .

Its tolerability profile appears to be significantly better than other SSRIs, despite its long history. Indeed, its affinity for serotonergic receptors is the lowest compared to other SSRIs (very high Ki).

Affinity profile:

Its affinity for muscarinic histaminergic receptors is almost zero. It is therefore a good molecule for moderate depression and for people sensitive to other SSRIs, as well as for the elderly. Several studies support this. Cognitive processes and behavior are only rarely altered (aggression, agitation, anxiety), compared to newer SSRIs. Weight gain is minimal and often nonexistent. Furthermore, sleep disturbances are significantly less frequent; fluvoxamine may even improve sleep in some cases. Withdrawal symptoms are mild to moderate, even in the event of abrupt discontinuation. Finally, it appears that this molecule causes fewer sexual dysfunctions, but studies show that this benefit is modest. The major drawback of fluvoxamine is the large number of interactions with other molecules ^[ 4 ] .

In October 2021, the TOGETHER double-blind randomized trial, conducted in Brazil, reported that early treatment of patients who tested positive for COVID-19 reduced their risk of hospitalization or emergency room admission, as well as the risk of death. However, the precise mechanism of action of the molecule against COVID -19 is the subject of debate ^[ 5 ] . Some specialists suggest that the molecule’s FIASMA (Functional Inhibitor of Acid Sphingomyelinase) properties may act on both the virus and inflammation through their ability to regulate ceramides ^[ 6 ] .